Eli Lilly And Co (LLY) Updates FY18 Earnings Guidance
Eli Lilly And Co (NYSE:LLY) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share guidance of $5.55-5.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.43. The company issued revenue guidance of $24.3-24.5 billion, compared to the consensus revenue estimate of $24.38 billion.Eli Lilly And Co also updated its FY 2018 guidance to $5.55-5.60 EPS.
Several research firms have commented on LLY. Guggenheim began coverage on Eli Lilly And Co in a research report on Monday, October 8th. They issued a buy rating on the stock. Zacks Investment Research upgraded Eli Lilly And Co from a hold rating to a buy rating and set a $129.00 price objective on the stock in a research report on Tuesday, October 9th. ValuEngine upgraded Eli Lilly And Co from a hold rating to a buy rating in a research report on Monday, October 8th. BMO Capital Markets upgraded Eli Lilly And Co from a market perform rating to an outperform rating and upped their price objective for the stock from $107.00 to $130.00 in a research report on Thursday, October 4th. Finally, JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the stock a buy rating in a research report on Friday, October 5th. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $111.19.
Shares of NYSE:LLY traded up $0.38 during midday trading on Thursday, reaching $110.10. 3,666,296 shares of the company’s stock traded hands, compared to its average volume of 4,229,162. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The firm has a market capitalization of $113.74 billion, a price-to-earnings ratio of 25.72, a price-to-earnings-growth ratio of 1.69 and a beta of 0.29. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.04%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
In related news, SVP Alfonso G. Zulueta sold 6,000 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the completion of the transaction, the senior vice president now directly owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the transaction, the insider now directly owns 3,148,647 shares of the company’s stock, valued at $44,081,058. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,885,271 shares of company stock valued at $133,643,752. 0.11% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Eli Lilly And Co (LLY) Updates FY18 Earnings Guidance” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/11/08/eli-lilly-and-co-lly-updates-fy18-earnings-guidance.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Fundamental Analysis
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.